Why is Mangalam Drugs falling/rising?

As of 11-Jul, Mangalam Drugs and Organics Ltd is experiencing a decline in its stock price, currently at Rs 86.00, reflecting a decrease of Rs 3.0 or 3.37%. The stock has underperformed its sector by 3.95% today and has been on a downward trend for the last two days, accumulating a total loss of 5.49%. Additionally, the stock touched an intraday low of Rs 84.94, indicating significant selling pressure. Over the past year, the stock has generated a return of -21.82%, while its profits have increased by 176.5%, suggesting a disconnect between profitability and stock performance. The company has a low ability to service debt, indicated by a high Debt to EBITDA ratio of 2.74 times, and a PAT for the quarter that has fallen by 97.6% compared to the previous four-quarter average, contributing to negative sentiment among investors. In the broader market context, the stock's short-term performance has been relatively better than the benchmark, with a 1-week return of +1.74% compared to the Sensex's -1.12%. However, the long-term outlook remains concerning, as the stock has consistently underperformed against the benchmark over the last three years, with a staggering -43.22% return compared to the Sensex's +51.67% over the same period. This consistent underperformance, combined with weak long-term fundamental strength and declining investor participation, paints a challenging picture for Mangalam Drugs, leading to its current price decline.